The Motley Fool··Josh Kohn-LindquistImmunityBio Gains 41% Following European Approval of Bladder Cancer Therapy
ImmunityBio shares surged 41% after Europe approved its bladder cancer therapy ANKTIVA, enabling commercialization across 30+ nations and opening significant revenue opportunities.
IBRXIOVAKRYSbiotechbladder cancer